Effect of Cumulative Intravenous Voriconazole Dose on Renal Function in Hematological Patients

Takeo Yasu; Takaaki Konuma; Seiichiro Kuroda; Satoshi Takahashi; Arinobu Tojo

doi:10.1128/AAC.00507-18

Effect of Cumulative Intravenous Voriconazole Dose on Renal Function in Hematological Patients

Antimicrob Agents Chemother. 2018 Aug 27;62(9):e00507-18. doi: 10.1128/AAC.00507-18. Print 2018 Sep.

Authors

Takeo Yasu^#¹, Takaaki Konuma^#², Seiichiro Kuroda¹, Satoshi Takahashi³, Arinobu Tojo³

Affiliations

¹ Department of Pharmacy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
² Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan tkonuma@ims.u-tokyo.ac.jp.
³ Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

^# Contributed equally.

Abstract

Intravenous voriconazole (VRC) is formulated by the incorporation of sulfobutylether-β-cyclodextrin (SBECD), which may accumulate to adversely affect renal function. However, the effect of long-term use of intravenous VRC on renal function is unclear. Our retrospective analysis of data confirmed that worsening of renal function was significantly associated with a cumulative dose of intravenous VRC (≥400 mg/kg), suggesting that a higher cumulative dose of intravenous VRC is a risk factor for renal dysfunction.

Keywords: cumulative dose; intravenous; renal function; sulfobutylether-β-cyclodextrin; voriconazole.

MeSH terms

Administration, Intravenous / adverse effects*
Adolescent
Adult
Aged
Antifungal Agents / adverse effects*
Female
Humans
Kidney / drug effects*
Male
Middle Aged
Renal Insufficiency / chemically induced*
Retrospective Studies
Voriconazole / adverse effects*
Young Adult
beta-Cyclodextrins / adverse effects

Substances

Antifungal Agents
beta-Cyclodextrins
SBE4-beta-cyclodextrin
Voriconazole